Orphai Therapeutics Inc. ("Orphai"), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant unmet need, today announced that ...

Among patients with SLE-associated PAH, those with rare PAH-related gene variants have a unique vasculopathy phenotype and worse outcomes.

Patients can “Outnumber PAH” by developing a strong support team, advises an unbranded educational campaign launched by Merck against pulmonary arterial hypertension (PAH), a rare, progressive disease ...

Bilateral lung transplantation in patients with pulmonary arterial hypertension (PAH) leads to comparable 1- and 5-year ...

Although more women than men have pulmonary arterial hypertension, several PAH medications are teratogenic, according to a ...

Pulmonary hypertension (PH) has a high mortality rate if untreated. Unfortunately, the disease is not consistently diagnosed or treated across the United States. To improve the diagnosis and care of ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic thromboembolic pulmonary hypertension, with specific patient selection ...

The presence of cardiovascular comorbidities has minimal effect on the efficacy of inhaled or oral treprostinil when used alongside oral monotherapy in patients with pulmonary arterial hypertension ...

In a recent review, researchers overviewed the challenging aspects of treating pulmonary arterial hypertension (PAH), highlight the genetic and etiological variability, and advocate for research to ...

"We had no preconceived idea if this drug would improve exercise capacity," said Luke Howard, MD, from Imperial College Healthcare NHS Trust in London. It was clear, however, that 6-minute walk tests ...

Please provide your email address to receive an email when new articles are posted on . In this cross-sectional study utilizing electrocardiography (ECG) and 2D echocardiography, Munje and colleagues ...